Wednesday, August 16, 2017 6:47:22 AM
its now going on 2 years trying to resuscitate AMBS - with no takers anywhere in sight
problem is / was / always will be is that AMBS's "business model" was flawed from the start
buying used niche biotech products cheap to take to the next level requires deep pockets, partners, collateralization, VC's, SEDA's, coupled with multiple years involving seasoned experience professionals vs that of a bush league x-college football player
AMBS ran aground financially advancing their suite of products through developmental hurdles that were too costly, too time consuming and ultimately into test trials that simply became unsustainable
equity distribution only lasts so long when you have no ROI for shareholders
Gerald lying about MJFF MANF Grant funding approval was the 1st in a series of habitual lies that caused an irreversible crack in the proverbial foundation wall of AMBS
http://www.amarantus.com/news/press-releases/detail/313/correction-amarantus-biosciences-updates-shareholders-on
boy CEO Gerald was "star-stuck" and was completely void of the realities of all inherent biopharma start-up costs, hurdles and time-to-market principles
Shelly Kraft of SNN Live became intuitively aware of this as well, when it became too little too late - as did Jason Napodano of Seeking Alpha
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM